Figure 3.

HMGA2 is required for rhabdomyosarcoma growth in vivo. A, doxycycline (Dox)-inducible shRNA successfully reduced HMGA2 protein levels. B, inducible shRNA against HMGA2 caused doxycycline-dependent cell growth inhibition and cell death. The inhibition/death phenotypes were observed in sh-HMGA2–infected cells but not inducible sh-NT–infected cells. Arrows indicate dying cells. C, knockdown of HMGA2 in ERMS cells reduces the time cells spend in S-phase and causes G₀–G₁ arrest. Doxycycline treatment led to a gradual decrease of cells in S-phase and accumulation of cells in G₀–G₁ phase. D, doxycycline-inducible shRNA shows that HMGA2 is required for rhabdomyosarcoma growth in vivo. *, P < 0.05, Student t test. +Dox group versus −Dox group at the same time point.